Early clinical evidence identified a potential role in patients with autoimmune cytopenias (e.g., ITP) secondary to chronic lymphocytic leukemia, who showed increased platelet counts and fewer episodes of autoimmune‐based cytopenic events following BTK inhibitor treatment [8, 9]. This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.